Mortality rate of COVID-19 infection in end stage kidney disease patients on maintenance hemodialysis: A systematic review and meta-analysis.
COVID-19
End stage kidney disease
Infection
Maintenance hemodialysis
Mortality
Systematic review
Journal
World journal of virology
ISSN: 2220-3249
Titre abrégé: World J Virol
Pays: United States
ID NLM: 101608353
Informations de publication
Date de publication:
25 Sep 2022
25 Sep 2022
Historique:
received:
01
02
2022
revised:
20
05
2022
accepted:
25
07
2022
entrez:
3
10
2022
pubmed:
4
10
2022
medline:
4
10
2022
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) has been the most talked-about disease of the past few years. Patients with significant comorbidities have been at particular risk of adverse outcomes. This study looked at the outcomes and risk factors for adverse outcomes among patients on chronic hemodialysis for end-stage renal disease, a group of patients known to be particularly susceptible to infectious complications. To assess outcomes and risk factors for adverse outcomes of COVID-19 infection among patients on chronic hemodialysis. We searched PubMed/MEDLINE, EMBASE, Of the 920 studies identified through the initial database search, only 17 were included in the final analysis. The studies included in the analysis were mostly carried out during the first wave. We found that COVID-19 incidence among patients on hemodialysis was significant, over 10% in some studies. Those who developed COVID-19 infection were most likely going to be hospitalized, and over 1 in 5 died from the infection. Intensive care unit admission rate was lower than the infection lethality rate. Biochemical abnormalities and dyspnea were generally reported to be associated with adverse outcomes. This systematic review confirms that patients on chronic hemodialysis are very high-risk individuals for COVID-19 infections, and a significant proportion was infected during the first wave. Their prognosis is overall much worse than in the general population, and every effort needs to be made to decrease their exposure.
Sections du résumé
BACKGROUND
BACKGROUND
Coronavirus disease 2019 (COVID-19) has been the most talked-about disease of the past few years. Patients with significant comorbidities have been at particular risk of adverse outcomes. This study looked at the outcomes and risk factors for adverse outcomes among patients on chronic hemodialysis for end-stage renal disease, a group of patients known to be particularly susceptible to infectious complications.
AIM
OBJECTIVE
To assess outcomes and risk factors for adverse outcomes of COVID-19 infection among patients on chronic hemodialysis.
METHODS
METHODS
We searched PubMed/MEDLINE, EMBASE,
RESULTS
RESULTS
Of the 920 studies identified through the initial database search, only 17 were included in the final analysis. The studies included in the analysis were mostly carried out during the first wave. We found that COVID-19 incidence among patients on hemodialysis was significant, over 10% in some studies. Those who developed COVID-19 infection were most likely going to be hospitalized, and over 1 in 5 died from the infection. Intensive care unit admission rate was lower than the infection lethality rate. Biochemical abnormalities and dyspnea were generally reported to be associated with adverse outcomes.
CONCLUSION
CONCLUSIONS
This systematic review confirms that patients on chronic hemodialysis are very high-risk individuals for COVID-19 infections, and a significant proportion was infected during the first wave. Their prognosis is overall much worse than in the general population, and every effort needs to be made to decrease their exposure.
Identifiants
pubmed: 36188740
doi: 10.5501/wjv.v11.i5.352
pmc: PMC9523330
doi:
Types de publication
Journal Article
Langues
eng
Pagination
352-361Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All authors report no relevant conflicts of interest for this article.
Références
Am J Kidney Dis. 2021 May;77(5):748-756.e1
pubmed: 33465417
BMC Nephrol. 2021 Jan 14;22(1):29
pubmed: 33446135
J Am Soc Nephrol. 2021 Feb;32(2):385-396
pubmed: 33154174
J Nephrol. 2020 Dec;33(6):1171-1187
pubmed: 32651850
Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2170-80
pubmed: 26567370
J Nephrol. 2021 Apr;34(2):315-323
pubmed: 33515380
Nephrol Dial Transplant. 2020 Dec 4;35(12):2083-2095
pubmed: 33275763
Kidney360. 2020 Jun 18;1(8):755-762
pubmed: 35372963
Clin Infect Dis. 2021 May 4;72(9):e206-e214
pubmed: 32674114
World J Virol. 2021 Jul 25;10(4):182-208
pubmed: 34367933
Cureus. 2020 Sep 11;12(9):e10373
pubmed: 33062496
Int J Gen Med. 2021 Aug 26;14:4837-4845
pubmed: 34475777
World J Clin Cases. 2021 Sep 26;9(27):7986-7997
pubmed: 34621855
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):303-310
pubmed: 32298981
Ann Intern Med. 2016 Oct 4;165(7):473-481
pubmed: 27479614
Med J Armed Forces India. 2022 Feb 10;:
pubmed: 35169379
J Am Soc Nephrol. 2021 Jan;32(1):151-160
pubmed: 32883700
BMJ Evid Based Med. 2021 Jun;26(3):107-108
pubmed: 32934000
Indian J Nephrol. 2022 Jan-Feb;32(1):16-21
pubmed: 35283577
Nephrol Dial Transplant. 2020 Aug 1;35(8):1338-1411
pubmed: 32871594
J Clin Med. 2021 Dec 13;10(24):
pubmed: 34945114
Front Endocrinol (Lausanne). 2020 Nov 30;11:599255
pubmed: 33329400
Intensive Care Med. 2020 Jul;46(7):1339-1348
pubmed: 32533197
Int Urol Nephrol. 2022 Jan;54(1):193-199
pubmed: 34132971
Nephron. 2022;146(5):469-480
pubmed: 35354143
Nephrol Dial Transplant. 2021 Nov 9;36(11):2094-2105
pubmed: 34132811
Am J Med Sci. 2022 Oct;364(4):444-453
pubmed: 35490703
Indian J Nephrol. 2021 Sep-Oct;31(5):442-448
pubmed: 34880553